Banner - NPPA Connect

Opinion|Videos|December 2, 2024

Spesolimab Dosing Regimens

Panelists discuss how spesolimab dosing regimens are tailored to individual patient needs, with an initial high-dose infusion followed by maintenance therapy based on clinical response and disease severity.

Episodes in this series

EP. 1 Revolutionizing GPP Management: The Efficacy and Safety of Spesolimab in Preventing Life-Threatening Flares

EP. 1 Revolutionizing GPP Management: The Efficacy and Safety of Spesolimab in Preventing Life-Threatening Flares

EP. 2 Study Objectives and Key Inclusion Criteria for GPP Patients

EP. 2 Study Objectives and Key Inclusion Criteria for GPP Patients

EP. 3 Spesolimab Dosing Regimens

EP. 3 Spesolimab Dosing Regimens

EP. 4 Primary and Secondary Endpoints

EP. 4 Primary and Secondary Endpoints

EP. 5 Demographics and Baseline Characteristics Across Spesolimab Dose Groups

EP. 5 Demographics and Baseline Characteristics Across Spesolimab Dose Groups

EP. 6 Spesolimab Efficacy Data

EP. 6 Spesolimab Efficacy Data

EP. 7 Fighting the Flare of GPP: Expert Insights on Spesolimab

EP. 7 Fighting the Flare of GPP: Expert Insights on Spesolimab

EP. 8 Spesolimab Safety Data

EP. 8 Spesolimab Safety Data

EP. 9 Final Thoughts: The Spesolimab and GPP Flare Reduction

EP. 9 Final Thoughts: The Spesolimab and GPP Flare Reduction

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

1 expert is featured in this series

Why Patient-Reported Outcomes Matter in Psoriasis Care

ByTina Bhutani-Jacques, MD

September 11th 2026

1 expert is featured in this series

Addressing Steroid Fear with Non-Steroidal Treatment Options in Psoriasis

ByTina Bhutani-Jacques, MD

September 4th 2026

1 expert is featured in this series

Setting Realistic Treatment Goals for Localized Plaque Psoriasis

ByTina Bhutani-Jacques, MD

September 4th 2026

1 expert is featured in this series

Skin Clearance and PsA Prevention with Biologics in Psoriasis

ByBruce Strober, MD, PhD

September 1st 2026

1 expert is featured in this series

Case 3: Redefining How We Classify Psoriasis Severity

ByTina Bhutani-Jacques, MD

August 28th 2026

Trending on Dermatology Times

How Emerging Androgenetic Alopecia Therapies Target DHT at the Scalp Level

Tildrakizumab Partially Reverses Epigenetic Aging in Psoriasis, Pilot Study Shows

Field-Directed Therapy Favored for Actinic Keratosis Management

Diet Linked to Improved Chronic Idiopathic Urticaria Control

From Biopsy to Biomarkers: Experts Navigate Skin Cancer Diagnosis and Staging